Subconjunctival Bevacizumab and Recurrent Pterygium

Instituto de Olhos de Goiania36 enrolled

Overview

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

1. Pacients with recurrent pterygium 2. Anti-VEGF therapy -Bevacizumab

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Recurrent Pterygium

Interventions

BevacizumabDRUG

One subconjunctival aplication of Bevacizumabe 0,5ml

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Recurrent pterygium Exclusion Criteria: * Pregnant or lactating women * History of myocardial infarction * History of stroke

Locations (1)

Instituto de Olhos de Goiania

Goiânia, Goiás, Brazil

Outcomes

Primary Outcomes

Pterygium size after subconjunctival bevacizumab

-Size of recurrent pterygium (measured in mm) after injection

Time frame: 8 weeks

Secondary Outcomes

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

-Number of patients with hyposphagma and irritative symptoms after subconjunctival injection

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.